[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antiplatelet-agents\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antiplatelet-agents":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100618148","how-often-does-the-fecal-test-for-occult-blood-turn-positive-after-using-blood-thinners-100618148",false,"NCT07327853","How Often Does the Fecal Test for Occult Blood Turn Positive After Using Blood Thinners?","Exploring the Prevalence and Potential Benefits of Fecal Immunochemical Test Before Ana After Use of Antiplatelet and Anticoagulant Agents","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Have an indication to use oral antiplatelet or anticoagulant agent(s).\n* Absence of past bleeding tendency of gastrointestinal disease.\n* Agrees to have the test done (FIT).\n* Agrees to sign the informed consent.\n\nExclusion Criteria:\n\n* Presence of past bleeding tendency of gastrointestinal disease.\n* Refusal to have the test done (FIT).\n* Refusal to sign the informed consent.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Blood thinner medications used for cardiovascular disease can cause gastrointestinal bleeding. Early detection of invisible bleeding by performing occult fecal blood test (called fecal immunochemical test, or FIT) can uncover serious disease in the stomach and intestine and enable the treating physician to refer the patient for further evaluation.",[24,25,26],"Gastrointestinal Bleeding","Antiplatelet Agents","Oral Anticoagulant Therapy",[28,29,30,31,32,33],"Occult fecal blood","Fecal Immunochemical Test (FIT)","Gastrointestinal bleeding","Antiplatelet agents","Oral anticoagulant agents","Cardiovascular disease","NOT_YET_RECRUITING","2025-12-25",{"date":37,"type":38},"2026-01-08","ACTUAL",{"date":40,"type":20},"2026-02-01",{"date":42,"type":20},"2027-04-30",{"name":44,"class":45},"Jordan Collaborating Cardiology Group","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100571660","phase-4-optimal-perioperative-antiplatelet-therapy-investigation-on-abdominal-surgery-after-coronary-stent-implantation-100571660","NCT06723145","Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation","OPERATION","Inclusion Criteria:\n\n* Patients with a history of coronary stenting and scheduled for abdominal surgery\n* Patients on a single antiplatelet agent\n\nExclusion Criteria:\n\n* Patients on dual antiplatelet therapy (DAPT)\n* Patients on anticoagulation therapy\n* Patients with a history of stent thrombosis\n* Patients with CHADS2 score \\>= 5\n* Patients at extremely high risk of bleeding and unable to continue preoperative aspirin\n* Patients incapable of consent, including those under 20 years of age\n* Other patients for whom either discontinuation or continuation of antiplatelet agents is deemed inappropriate by the attending physician","20 Years",{"count":56,"type":20},1200,"INTERVENTIONAL",[59],"PHASE4","The purpose of this study is to evaluate the impact of perioperative aspirin continuation on clinical outcomes in patients with a history of coronary stent implantation who are scheduled for abdominal surgery.",[25,62],"Perioperative Care",[64,65,66,67,68],"antiplatelet agents","perioperative care","coroanry artery disease","abdominal disease","noncardiac surgery","RECRUITING","2025-02-09",{"date":72,"type":38},"2025-02-11",{"date":74,"type":38},"2025-01-20",{"date":76,"type":20},"2027-03-31",{"name":78,"class":45},"Kyoto University"]